Itragerm

Itraconazole, the active ingredient in Itragerm, is an azole antifungal presented as an oral formulation for oral use. It is employed to treat systemic mycoses and selected dermatophytosis and candidiasis infections in adult patients.

GNH USA supplies Itragerm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Itraconazole is used to treat fungal infections across several disease categories.

Aspergillosis: effective in treating invasive disease caused by Aspergillus species. Blastomycosis: clears systemic infection caused by Blastomyces dermatitidis. Histoplasmosis: resolves disseminated histoplasma infection. Sporotrichosis: manages cutaneous and systemic sporotrichal disease. Dermatophytosis: eradicates skin infections caused by dermatophyte fungi. Candidiasis: treats mucosal and systemic Candida infections.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: upset stomach and feeling of queasiness. - Headache: mild to moderate head pain. - Rash: skin redness or itching. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice. - Congestive heart failure: fluid retention and worsening cardiac function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Itraconazole, clinicians should observe several precautionary measures to ensure patient safety. - Liver function monitoring: assess baseline and periodic hepatic enzymes. - Cardiac assessment: avoid use in patients with existing heart failure. - Drug interaction review: evaluate concomitant medications that affect CYP3A4. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Hypersensitivity: discontinue if allergic reactions such as rash or anaphylaxis occur. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Itraconazole has a notable potential for drug‑drug interactions, primarily through CYP3A4 inhibition.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): may cause toxic itraconazole levels. - Drugs that prolong QT interval (e.g., quinidine, sotalol): increased risk of cardiac arrhythmia. - Certain anti‑arrhythmic agents (e.g., amiodarone): may lead to severe cardiac effects.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of myopathy, adjust dose. - Oral contraceptives: reduced efficacy, consider alternative contraception. - Antacids or proton pump inhibitors: may decrease itraconazole absorption, separate dosing times.